8-K: IO Biotech Stockholders Elect Director and Ratify Auditor at 2025 Annual Meeting

IO Biotech, Inc. announced the results of its 2025 Annual Meeting of Stockholders, where David Smith was elected as a Class I Director and EY Godkendt Revisionspartnerselskab was ratified as the independent registered public accounting firm.

Summary

• IO Biotech, Inc. held its 2025 Annual Meeting of Stockholders on June 5, 2025.
• Stockholders elected David Smith as a Class I Director, with 40,444,898 votes For and 3,010,542 votes Withheld.
• The appointment of EY Godkendt Revisionspartnerselskab as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 51,581,966 votes For, 183,927 Against, and 312,045 Abstain.

Sentiment

Score: 7

Explanation: The document reports on routine corporate governance matters where all proposals passed as expected, indicating stable operations and shareholder alignment on these specific items. There are no negative surprises or significant positive developments beyond the expected course of business.

Positives

• Both proposals presented at the Annual Meeting were approved by stockholders, indicating continued support for the company's governance and financial oversight.
• David Smith was successfully elected as a Class I Director, ensuring continuity in board leadership.
• The ratification of EY Godkendt Revisionspartnerselskab provides stability in the company's independent auditing function.

Negatives

• No specific negative outcomes were reported from the Annual Meeting results.

Risks

• No specific risks were mentioned in this 8-K filing.

Future Outlook

This 8-K filing primarily reports on the results of the annual stockholder meeting and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Management Comments

• The report was signed by Mai-Britt Zocca, Ph.D., Chief Executive Officer, indicating official company communication of the meeting results.

Industry Context

This filing is a routine corporate governance update, reporting the outcomes of an annual stockholder meeting. It does not provide information that directly relates to broader industry trends or competitive dynamics within the biotechnology or pharmaceutical sector.

Comparison to Industry Standards

• This 8-K filing reports on standard corporate governance matters, specifically the results of an annual stockholder meeting. The election of directors and ratification of auditors are routine procedures for publicly traded companies and do not lend themselves to direct comparison with specific industry projects or financial results of comparable companies.
• The voting percentages for director elections and auditor ratifications are generally high across public companies, and the results for IO Biotech appear consistent with typical outcomes for such proposals.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders**: The election of a director and ratification of the auditor are standard governance procedures that provide shareholders with transparency and oversight regarding the company's leadership and financial reporting.

Next Steps

• David Smith will serve as a Class I director until the Company's 2026 Annual Meeting of Stockholders.
• EY Godkendt Revisionspartnerselskab will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Recommendation

Keywords

IO Biotech, IOBT, Annual Meeting, Stockholders Meeting, Director Election, Auditor Ratification, Corporate Governance, SEC Filing, 8-K